# Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

> **NCT03965468** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ETOP IBCSG Partners Foundation** · enrollment: 96 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- Stage IV
- Oligometastasis

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **RADIATION:** Stereotactic body radiation therapy (SBRT)
- **PROCEDURE:** Surgical resection - definitive local treatment.
- **RADIATION:** Radical radiotherapy - definitive local treatment.
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT03965468
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-19
- **Primary completion:** 2026-08
- **Final completion:** 2026-12
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03965468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03965468, "Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03965468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*